首页|间充质干细胞及其外泌体治疗器官纤维化的研究进展

间充质干细胞及其外泌体治疗器官纤维化的研究进展

Research Progress of Mesenchymal Stem Cells and Their Exosomes in the Treatment of Organ Fibrosis

扫码查看
器官纤维化以细胞外基质(ECM)过度沉积为特征,是慢性脏器疾病发展为癌症的中间病理过程.目前尚无有效的抗纤维化方法.间充质干细胞(MSCs)作为多能干细胞,不仅可通过增殖分化、免疫调节、旁分泌以及归巢作用,促进组织纤维化的修复,而且其分泌的外泌体亦可通过将其活性成分转移到损伤细胞,或作为递送载体靶向作用于受体细胞,为治疗器官纤维化疾病提供了新的选择.针对肺、肝、肾、心脏、皮肤以及胰腺纤维化,综述MSCs及其外泌体在治疗器官纤维化疾病中的机制和应用,为后期发展纤维化的干细胞疗法提供参考.
Organ fibrosis is characterized by excessive deposition of extracellular matrix(ECMs),and is an intermediate pathological process of chronic organ disease developing into cancer.At present,there is still no effective anti-fibrosis strategy.As pluripotent stem cells,mesenchymal stem cells(MSCs)can promote the repair of fibrotic tissues by differentiation,immune regulation,paracrine and homing;besides,their exosomes(MSC-Exos)as the delivery vectors show great potential in the treatment of organ fibrosis by transferring their active components to injured cells or targeting recipient cells,providing a new option for the treatment of organ fibrosis.Based on liver fibrosis,lung fibrosis,kidney fibrosis,cardiac fibrosis,skin fibrosis and pancreatic fibrosis,this paper summarizes the mechanisms and applications of MSCs and MSC-Exos in the treatment of organ fibrosis,in the hope of providing new insights to further develop stem-cell therapy for fibrosis.

mesenchymal stem cellexosomeorgan fibrosistargeted therapydrug delivery

熊宇、刘红梅、李贤哲、王硕、韩露、何黎黎、袁志翔

展开 >

西南民族大学药学院,四川成都 610041

间充质干细胞 外泌体 器官纤维化 靶向治疗 药物递送

国家自然科学基金中央高校基本科研基金四川省中央引导地方科技发展专项四川省中医药管理局科学技术研究专项

8197326520211072021ZYD00702020LC0199

2024

药学进展
中国药科大学

药学进展

影响因子:0.624
ISSN:1001-5094
年,卷(期):2024.48(6)